Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers a wide selection of fully verified anti-GLP-1 recombinant antibodies, each precisely tailored to satisfy the demands of researchers. Our premium selection has undergone rigorous validation to ensure great performance in a variety of applications, including WB, IHC, IF, FC, ELISA, etc. Using our superior recombinant antibody technology, we provide researchers with trustworthy resources to help them with their research in cell biology, disease modeling, and drug discovery.
Glucagon-like peptide-1 (GLP-1) has emerged as a significant therapeutic target for metabolic disorders, notably type 2 diabetes and obesity. This incretin hormone regulates glucose levels by increasing insulin production from pancreatic beta cells while decreasing glucagon release. Additionally, GLP-1 induces satiety and slows gastric emptying, contributing to weight management. By mimicking the actions of endogenous GLP-1, GLP-1 receptor agonists have revolutionized the treatment of these conditions, offering substantial benefits in glycemic control, weight loss, and cardiovascular health.
Glucagon-like peptide-1; GLP-1.
Glucagon-like peptide-1 (GLP-1) is an incretin derived from the transcription product of the proglucagon gene. The major source of GLP-1 in the body is the intestinal L cell that secretes GLP-1 as a gut hormone. The biologically active forms of GLP-1 are: GLP-1-(7-37) and GLP-1-(7-36) NH2. Those peptides result from selective cleavage of the proglucagon molecule.
Creative Biolabs presents a wide range of recombinant anti-GLP-1 antibodies, meticulously engineered to ensure exceptional specificity and binding affinity. These antibodies cater to various research needs, from fundamental studies to therapeutic advancements, and are available in multiple formats. Our cutting-edge platform empowers us to deliver high-quality resources that enhance our insights into cellular and molecular biology, focusing on pivotal areas such as immunology and cancer research.
Table 1. Featured anti-GLP-1 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
MHH-399 | Recombinant Human Anti-GLP-1 Antibody | Human | Human IgG | WB, ELISA, IHC, FS |
MOB-399 | Recombinant Anti-GLP-1 Antibody | Mouse | Mouse | WB, Dot, FuncS |
Gly-043LC | Recombinant Anti-Human GLP-1 Antibody (Fc glycosylation) | Human | Human | ELISA |
Creative Biolabs offers a varied range of proven recombinant antibodies targeting GLP-1. Our antibodies are precisely developed to provide exceptional specificity, stability, and efficacy. We guarantee that every antibody satisfies the most exacting industry standards by using extensive quality control procedures. These premium antibodies are critical aids to researchers studying the role of GLP-1 in metabolic disorders and other related diseases.
Creative Biolabs leverages cutting-edge genetic engineering methodologies to develop high-quality anti-GLP-1 antibodies, ensuring reliable availability for diverse research purposes.
Featured Anti-GLP-1 Recombinant Antibody Production Platforms
Fig.1 Milligram-scale anti-GLP-1 recombinant antibody production.
Fig.2 Gram-scale anti-GLP-1 recombinant antibody production.
Creative Biolabs provides a diverse selection of high-quality anti-GLP-1 recombinant antibodies tailored to meet global research demands.
Fig.3 Full-length anti-GLP-1 recombinant antibody production and modalities.
Table 2. Public drug targeting GLP-1.
Highest Phase | Mechanism of Action | Product Category | Condition | Organization |
Bostal Drug Delivery iX Biopharma Lexaria Bioscience MSD KK Novo Nordisk (Originator) |
Launched - 2018 |
Glucagon-Like Peptide 1 (GLP-1) Analogues Polypeptides, from 10 AA to 40 AA Recombinant proteins |
Alcoholic liver disease Cardiovascular Disorders Chronic kidney disease Dementia, Alzheimer's type Diabetes Diabetes type 2 Non-alcoholic steatohepatitis (NASH) Obesity Parkinson's disease Peripheral arterial disease (PAD) Retinopathy, diabetic |
|
Cipla Lilly (Originator) Lupin Sumitomo Dainippon Pharma (Sumitomo Pharma) Sumitomo Pharma |
Launched - 2014 |
Fc Fusion Proteins Glucagon-Like Peptide 1 (GLP-1) Analogues Polypeptides, from 41 AA |
Cardiovascular Disorders Diabetes Diabetes type 2 |
|
GlaxoSmithKline (GSK) GSK (Originator) Human Genome Sciences (GSK) |
Launched - 2014 |
Fusion Proteins Glucagon-Like Peptide 1 (GLP-1) Analogues Polypeptides, from 41 AA |
Diabetes type 1 Diabetes type 2 Heart failure |
|
4P-Pharma Cincinnati Children's Hospital Med Cent Imperial College Lancaster University Nanexa Novo Nordisk (Originator) |
Launched - 2009 |
Glucagon-Like Peptide 1 (GLP-1) Analogues Polypeptides, from 10 AA to 40 AA Recombinant proteins |
Amyotrophic lateral sclerosis Arthritis, psoriatic Cardiovascular Disorders Dementia, Alzheimer's type Diabetes type 1 Diabetes type 2 Diabetic nephropathy Diabetic neuropathy Maturity onset diabetes of the young (MODY) Non-alcoholic steatohepatitis (NASH) Obesity Osteoarthritis, knee Parkinson's disease Sleep apnea |
|
Gmax Biopharm (Originator) | Phase III |
Fusion Proteins Humanized Monoclonal Antibodies Polypeptides, from 41 AA |
Diabetes type 2 Obesity |
|
Hanmi (Originator) Sanofi |
Phase III |
Fc Fusion Proteins Glucagon-Like Peptide 1 (GLP-1) Analogues Polypeptides, from 41 AA |
Diabetes Diabetes type 2 Obesity |
|
Shanghai Yinnuo Pharmaceutical Technology University of Toronto (Originator) |
Phase II/III |
Fc Fusion Proteins Glucagon-Like Peptide 1 (GLP-1) Analogues Polypeptides, from 41 AA |
Diabetes Diabetes type 2 |
|
Amgen (Originator) | Phase II |
Fusion Proteins Glucagon-Like Peptide 1 (GLP-1) Analogues Human Monoclonal Antibodies Immunoconjugates Polypeptides, from 41 AA |
Diabetes type 2 Obesity |
|
China Shijiazhuang Pharmaceutical (CSPC) (CSPC Pharmaceutical Group) CSPC Pharmaceutical Group I-Mab Biopharma (Originator) |
Phase II |
Fc Fusion Proteins Glucagon-Like Peptide 1 (GLP-1) Analogues Polypeptides, from 41 AA |
Dementia, Alzheimer's type Diabetes type 2 Non-alcoholic steatohepatitis (NASH) Obesity |
|
Hanmi (Originator) | Phase II |
Fc Fusion Proteins Polypeptides, from 41 AA |
Idiopathic pulmonary fibrosis Non-alcoholic fatty liver disease (NAFLD) Non-alcoholic steatohepatitis (NASH) Obesity Parkinson's disease Primary biliary cholangitis Sclerosing cholangitis |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
To learn more about our high-quality anti-GLP-1 recombinant antibody products, including their specific applications, target species, and detailed product specifications, please feel free to contact us. Our experienced team is glad to help you identify the best antibody solution for your research needs.